Adocia Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets
July 29 2021 - 12:00PM
Business Wire
Regulatory News:
Under the liquidity agreement entrusted by Adocia (Paris:ADOC)
to Kepler Capital Markets, the following resources were listed on
the liquidity account on June 30th, 2021:
- 33,978 shares
- € 100,306.46
- Number of executions on buy side on semester: 491
- Number of executions on sell side on semester: 407
- Traded volume on buy side on semester: 74,577 shares for €
740,037.47
- Traded volume on sell side on semester: 71,132 shares for €
735,699.33
As a reminder:
• the following resources appeared on the last half year
statement on December 31, 2020 on the liquidity account:
- 30,533 shares
- € 104,644.6
• the following resources appeared on the liquidity account when
the activity started:
- 15,026 shares
- € 300,000.00
The liquidity agreement complies with AMF Decision n° 2018-01
dated 2nd July 2018, introducing liquidity agreements on equity
securities as permitted market practice
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring five clinical-stage products and several
pre-clinical products. The proprietary BioChaperone® technological
platform is designed to enhance the effectiveness and/or safety of
therapeutic proteins while making them easier for patients to use.
Adocia customizes BioChaperone® to each protein for a given
application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: two combinations of rapid acting insulin
analogs and Pramlintide (BioChaperone® Lispro Pram and
BioChaperone® Aspart Pram), a combination of insulin glargine with
GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In
addition, there are two bi-hormonal products for the treatment of
obesity: a combination of glucagon and exenatide (BioChaperone®
GluExe) and a combination of pramlintide and exenatide
(PramExe).
Adocia recently added a preclinical program to its pipeline with
a cell therapy initiative focused on development of a hydrogel
scaffold for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 20, 2021
(a copy of which is available at www.adocia.com) and to the
development of economic conditions financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Adocia to be
materially different from such forward-looking statements. This
press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210729005779/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu Ph: +49 89 210
228 0
The Ruth Group Adocia Investor Relations USA Brett
Mermelstein Senior Account Executive
bmermelstein@theruthgroup.com Ph.: +1 267 639 0721
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024